BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 872 filers reported holding BAXTER INTL INC in Q2 2016. The put-call ratio across all filers is 0.49 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $92,510,000 | +65.0% | 1,405,500 | +93.2% | 2.86% | +98.7% |
| Q3 2018 | $56,083,000 | +36.2% | 727,500 | +30.5% | 1.44% | +38.1% |
| Q2 2018 | $41,166,000 | -39.6% | 557,500 | -46.8% | 1.04% | -30.4% |
| Q1 2018 | $68,129,000 | -11.6% | 1,047,500 | -12.2% | 1.50% | -20.7% |
| Q4 2017 | $77,083,000 | -9.3% | 1,192,500 | -12.0% | 1.88% | -17.9% |
| Q3 2017 | $85,026,000 | -9.7% | 1,355,000 | -12.9% | 2.30% | -16.4% |
| Q2 2017 | $94,140,000 | -5.0% | 1,555,000 | -18.6% | 2.74% | -9.6% |
| Q1 2017 | $99,053,000 | -8.9% | 1,910,000 | -22.1% | 3.03% | -5.3% |
| Q4 2016 | $108,684,000 | +21.8% | 2,451,150 | +30.7% | 3.20% | +32.0% |
| Q3 2016 | $89,250,000 | -4.3% | 1,875,000 | -9.1% | 2.43% | -26.5% |
| Q2 2016 | $93,266,000 | -11.8% | 2,062,500 | -19.9% | 3.30% | -11.2% |
| Q1 2016 | $105,773,000 | +15.5% | 2,574,815 | +7.3% | 3.72% | +50.6% |
| Q4 2015 | $91,560,000 | +123.0% | 2,400,000 | +92.0% | 2.47% | +169.1% |
| Q3 2015 | $41,063,000 | – | 1,250,000 | – | 0.92% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |